Client Care






COVID-19 : How to use the test

June 5, 2020


Products Range

New product:

Ag Respi-Strip

BL-RED Range

Resist Range









Immunochromatographic Range

Pathogens detection

40/41 Adenovirus


Clostridium difficile

Cryptosporidium & Giardia

Rotavirus & 40/41 Adenovirus


Helicobacter pylori

Influenza A & B viruses


Respiratory Adenovirus

Rotavirus & Adenovirus


Respiratory Syncytial Virus (RSV)

Streptococcus (group A)

Trypanosoma brucei gambiense (HAT)

Quatro-VeT (Veterinary)

Molecular Range

Pseudomonas aeruginosa

Scientific partners



PARADIS (Biowin)

AquaVir (FP7)

Nareb (FP7)

Euroleish (H2020-MSCA-ITN)

ebolaMoDRAD (IMI-2)


Products  >  Human-Field  >  RSV  >  Science



• Multicenter evaluation of BD Veritor System and RSV K-SeT for rapid detection of respiratory syncytial virus in a diagnostic laboratory setting

Jonckheere S, Verfaillie C, Boel A, Van Vaerenbergh K, Vanlaere E, Vankeerberghen A, De Beenhouwer H

Diagn Microbiol Infect Dis. 2015 May 27. pii: S0732-8893(15)00092-3


The recently introduced BD Veritor System RSV laboratory kit (Becton Dickinson, Sparks, MD, USA) with automatic reading was evaluated and compared with the RSV K-SeT (Coris BioConcept, Gembloux, Belgium) for the detection of respiratory syncytial virus (RSV) using 248 nasopharyngeal aspirates of children younger than 6 years old with respiratory tract infection. Compared to reverse transcriptase polymerase chain reaction as gold standard, both tests had an identical sensitivity of 78.1% and a specificity of 96.8% and 95.8% for the
BD Veritor System and RSV K-SeT, respectively. Both antigen tests can be used to reliably confirm RSV in young children. However, a negative result does not definitively exclude the presence of RSV



• Final Report External Quality Assessment Scheme (EQAS)

June/July 2010 Virus Immunology – Respiratory Syncytial Virus (359)

Detection of RSV infections


• Evaluation of the performance of RSV Respi-Strip in comparison with cell culture and reverse transcriptase PCR.

Wybo I, Piérard D, Stevens D, Soetens O and Lauwers S

ECCMID, 2009

Performance of RSV RespiStrip


• Impact on viral pathogen yield of the absence of cells in nasopharyngeal aspirate specimens.

Piérard D, Stevens D, Mignolet J, Moriau L, Vergalle K, Lauwers S.

ECCMID, 2007

Impact on viral pathogen


• Direct antigen detection of the RS-virus using Binax NOW RSV Test- and Coris BioConcept RSV Respi-Striprapid diagnostic test-methods.

Salonen, Hannaleena.

Bachelor's thesis presented in May 2006.

Direct antigen detection of RSV


• Rapid Detection of RSV: Performance of X/pectTM RSV and RSV Respi-StripTM, Two New Immunochromatographic Assays.

Karnauchow TM, and Milk R

Poster presented at the Pan American Society for Clinical Virology (PASCV), April 25-28,


Rapid detection of RSV


• Comparison of a Rapid Immunochromatographic Diagnostic Test with Viral Culture to Detect Respiratory Syncytial Virus in Nasopharyngeal Specimens.

Van den Wijngaert S, De Foor M, Van Beers D

ASM-ICAAC 44th, October 30th-November 2nd, 2004.

Detection of RSV in nasopharyngeal specimens


• Summary of clinical studies of the RSV Uni-Strip in 2004-2005 winter.

Clinical studies, Japan, 2005.

RSV UniStrip Clinical Survey


• Comparison of the RSV respi-strip with direct fluorescent-antigen detection for diagnosis of respiratory syncytial virus infection in pediatric patients.

Gregson D, Lloyd T, Buchan S, Church D.

J Clin Microbiol. 2005 Nov;43(11):5782-3.


The RSV Respi-Strip was compared to the SimulFluor respiratory screen for detecting respiratory syncytial virus in nasopharyngeal aspirates from pediatric patients. Of samples tested, 115/239 (49%) were positive by direct fluorescent-antigen detection. The sensitivity and specificity of the RSV Respi-Strip were 92% (95% confidence interval [CI], 86% to 96%) and 98% (95% CI, 94% to 100%), respectively, with a diagnostic efficiency of 95%.


• Respiratory syncytial virus outbreak defined by rapid screening in a neonatal intensive care unit.

Dizdar EA, Aydemir C, Erdeve O, Sari FN, Oguz S, Uras N, Dilmen U.

J Hosp Infect. 2010 Aug;75(4):292-4. Epub 2010 Mar 17.


Palivizumab is currently licensed for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants and children with chronic lung disease, with a history of preterm birth, or with haemodynamically significant congenital heart disease, but its routine use during outbreaks in neonatal intensive care units (NICUs) is not currently recommended. Here we report an outbreak in a NICU detected during a screening trial for RSV infection using a rapid antigen test (Respi-Strip((R))). Eleven preterm infants in our NICU tested positive for RSV during January 2009. Subsequent testing of the remaining infants in the NICU revealed two additional asymptomatic cases. In addition to precautions against cross-infection, palivizumab prophylaxis was administered to the remaining 37 premature infants. Two days after treatment, RSV was detected in two additional infants who had become symptomatic. To our knowledge this is the largest RSV outbreak in a NICU to be identified at an early stage by rapid testing and effectively controlled by infection control measures and palivizumab prophylaxis.



More information:



Home   -   Site Map   -   Privacy Policy   -   Contact   -   FAQ                   All rights reserved CorisBioconcept SPRL 1996-2012©                 

Web traffic Optimisation

Design, Programming & hosting
Impact communication